e.l.f. Beauty, Inc. (ELF) Q2 2025 Earnings Call Transcript

e.l.f. Beauty, Inc. (NYSE:ELF) Q2 2025 Earnings Conference Call November 6, 2024 4:30 PM ET

Company Participants

KC Katten – Vice President-Corporate Development and Investor Relations
Tarang Amin – Chairman and Chief Executive Officer
Mandy Fields – Senior Vice President and Chief Financial Officer

Conference Call Participants

Ashley Helgans – Jefferies
Olivia Tong – Raymond James
Bill Chappell – Truist Securities
Peter Grom – UBS
Dara Mohsenian – Morgan Stanley
Oliver Chen – TD Cowen
Susan Anderson – Canaccord Genuity
Anna Lizzul – Bank of America
Linda Bolton Weiser – D.A. Davidson
Korinne Wolfmeyer – Piper Sandberg
Mark Altschwager – Baird
Mark Astrachan – Stifel
Rupesh Parikh – Oppenhimer

KC Katten

Thank you for joining us today to discuss e.l.f. Beauty’s Second Quarter Fiscal 2025 Results. I’m KC Katten, Vice President of Corporate Development and Investor Relations. With me today are Tarang Amin, Chairman and Chief Executive Officer; and Mandy Fields, Senior Vice President and Chief Financial Officer. We encourage you to tune into our webcast presentation for the best viewing experience, which you can access on our website at investor.elfbeauty.com.

Since many of our remarks today contain forward-looking statements, please refer to our earnings release and reports filed with the SEC, where you’ll find factors that could cause actual results to differ materially from these forward-looking statements. In addition, the company’s presentation today includes information presented on a non-GAAP basis. Our earnings release contains reconciliations of the differences between the non-GAAP presentation and the most directly comparable GAAP measure.

With that, let me turn the webcast over to Tarang.

Tarang Amin

Thank you, KC, and good afternoon everyone. Today we’ll discuss the drivers of our second quarter results and our raised outlook for fiscal 2025. I want to start by recognizing the e.l.f. Beauty team. Q2 marked yet another quarter of consistent category leading growth. In